Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

3(75.0%)

N/A

1(25.0%)

4Total

Phase 2(3)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT01879657Not ApplicableCompleted

68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)

Role: collaborator

NCT05785663Completed

AminoMedixTM for Kidney Protection During Radionuclide Therapy

Role: lead

NCT01237457Phase 2Completed

177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms

Role: collaborator

NCT04276597Phase 2Withdrawn

Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.

Role: lead

NCT02282137Phase 2Unknown

68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer

Role: collaborator

All 5 trials loaded